7,12-Dimethylbenz(a)anthracene

From Wikipedia, the free encyclopedia
Jump to: navigation, search
The correct title of this article is 7,12-Dimethylbenz[a]anthracene. It appears incorrectly here because of technical restrictions.
7,12-Dimethylbenz[a]anthracene[1]
DMBA.png
7,12-Dimethylbenz(a)anthracene ballstick.png
Names
IUPAC name
7,12-Dimethylbenzo[a]phenanthrene
Other names
7,12-Dimethylbenzanthracene; 7,12-Dimethyltetraphene; 1,4-Dimethyl-2,3-benzophenanthrene
Identifiers
57-97-6 YesY
ChEBI CHEBI:254496 YesY
ChEMBL ChEMBL329673 YesY
ChemSpider 5779 YesY
Jmol-3D images Image
PubChem 6001
Properties
C20H16
Molar mass 256.34 g·mol−1
Melting point 122 to 123 °C (252 to 253 °F; 395 to 396 K)
Hazards
Main hazards T (Toxic)
R-phrases R45 R22
S-phrases S53 S36/37 S45
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 YesY verify (what isYesY/N?)
Infobox references

7,12-Dimethylbenz[a]anthracene (DMBA) is an immunosuppressor and a powerful organ-specific laboratory carcinogen.[2] DMBA is widely used in many research laboratories studying cancer. DMBA serves as a tumor initiator. Tumor promotion can be induced with treatments of 12-O-tetradecanoylphorbol-13-acetate (TPA) in some models of two-stage carcinogenesis.[3] This allows for a greatly accelerated rate of tumor growth, making many cancer studies possible.

References[edit]

  1. ^ 7,12-Dimethylbenz(a)anthracene at Sigma-Aldrich
  2. ^ Miyata M, Furukawa M, Takahashi K, Gonzalez FJ, Yamazoe Y (2001). "Mechanism of 7, 12-Dimethylbenz[a]anthracene-Induced Immunotoxicity: Role of Metabolic Activation at the Target Organ". Jpn J Pharmacol 86: 302–309. doi:10.1254/jjp.86.302. 
  3. ^ Sung YM, He G, Fischer, SM (2005). "Lack of Expression of the EP2 but not EP3 Receptor for Prostaglandin E2 Results in Suppression of Skin Tumor Development". Cancer Res 65: 9304–9311. doi:10.1158/0008-5472.can-05-1015.